Do you face the challenge of recruiting and retaining rare disease patients for orphan drug clinical trials? Now, discover how you can boost participation, enhance outcomes and speed drug development in this competitive market. Join Dr.

Key Learning Objectives ? Understand the regulatory environment and legal framework of the evaluation of abuse potential of CNS-active compounds under development. ? Recognize the critical steps defining the regulatory strategy of the assessment of abuse potential of CNS-active compounds in general, and in particular of analgesics. ? Identify abuse potenti

All small molecules with systemic bioavailability must conduct a study to assess that drug's proarrhythmic liability during clinical development, usually before Phase III. Updated guidance from the International Conference on Harmonisation (ICH) now allows for specific Phase I data as a reasonable substitute for a Thorough-QT (TQT) dedicated trial.

Sponsors running clinical research studies face enormous pressures today. From complex study designs, industry cost constraints, new geographical locations and significant technological advancements, there are many challenges to address.

Today's shift from organ-based symptom relief to mechanism-based treatment can be effective in treating multiple inflammatory conditions, but many factors must be considered to translate inflammation from the bench to the clinic.

In this webinar, Dr. Jon Plehn, MD, vice president of Cardiovascular Medicine at Covance will be joined by Dr.

Industry standard timelines for end-to-end completion of a typical renal or hepatic impairment trial may be up to 18-22 months. Over the past 10 years, Covance has developed a built-for-purpose model for executing impairment studies resulting in a 36% reduction of time for end-to-end services.

? Drug development business of LabCorp ? World's most comprehensive drug development company ? Offers a consultative approach from biomarker discovery and assay development to global, multi-year trial execution in vaccines development

View this webinar to learn more about: ? Factors driving the importance of biomarkers in immuno-oncology development ? How to leverage key technologies - flow cytometry, immunohistochemistry and next-generation sequencing ? A real-world example of how to tackle the challenge of effective patient recruitment ? The best way to engage a CRO / lab partner and

Bioengineered blood vessels have great potential to improve the lives of hemodialysis patient.